News
To support the world-wide urgent need for a vaccine against COVID-19 disease, Var2 Pharmaceuticals and VarCT Diagnostics have made their protein engineering and production pipelines available to a joint vaccine program ongoing at the University of Copenhagen in collaboration with AdaptVac (www.adaptvac.com) and Bavarian Nordic (OMX: BAVA, OTC: BVNRY). Read …
Read MoreVar2 Pharmaceuticals has been selected as the European winner of the 2020 Advance Biotech Grant Program (SigmaMillipore). VAR2 Pharmaceuticals was chosen for its development of a promising novel pre-clinical cancer drug-conjugate treatment with the potential to treat multiple types of human adult and childhood solid tumors. VAR2 Pharmaceuticals ApS …
Read MoreOn May 7th, Bloom Burton & Co. announced that VAR2 Pharmaceuticals’ co-founder and member of the Board, Prof. Poul Sorensen, is one of the three final nominees to the prestigious 2019 Bloom Burton Award, honouring individuals making the greatest contributions to Canada’s healthcare industry in the past years. We are very …
Read MoreVAR2 Pharmaceuticals ApS
Ole Maaløes Vej 3
DK-2200 Copenhagen N
CVR: 34621942
T: +45 78 70 19 00